Outsourcing to the right testing laboratory can give drug developers a competitive edge by maximising efficiencies and expediting the regulatory approval process. But outsourcing often comes with the risk of stepping into an unknown and untested relationship.

While evidence from psilocybin studies in rodents demonstrates long–term coping strategy and cognitive function behavioural effects that can be compared to those of traditional antidepressant treatments, a “gold-standard” protocol for assessing the behavioural effects of psychedelics has yet to be established.